Annals of Oncology 14:1051-1056, 2003
© 2003 European Society for Medical Oncology
Original Paper |
Eicosapentaenoic acid restores tamoxifen sensitivity in breast cancer cells with high Akt activity


1 Division of Medical Oncology, University of Texas Health Science Center at San Antonio, San Antonio, TX; 2 The Johns Hopkins Oncology Center, Johns Hopkins University, Baltimore, MD, USA
Received 24 January 2003; revised 18 February 2003; accepted 3 April 2003
Background:
Tamoxifen resistance is the underlying cause of treatment failure in a significant number of patients with breast cancer. Activation of Akt, a downstream mediator in the phosphatidylinositol 3-kinase (PI3K) signaling pathway has been implicated as one of the mechanisms involved in tamoxifen resistance. Breast cancers with heightened Akt activity are frequently associated with an aggressive disease and resistance to chemo- and hormone-therapy-induced apoptosis. Inhibition of PI3K restores apoptotic response to tamoxifen in hyperactive Akt cells. Therefore, agents that demonstrate Akt inhibitory properties are attractive therapeutic agents for the treatment of hormone-resistant breast cancer. n-3 fatty acids have proven to be potent and efficacious broad-spectrum protein kinase inhibitors.
Materials and methods:
In this study we demonstrate that the n-3 fatty acid, eicosapentaenoic acid (EPA), inhibits the kinase activity of Akt. Co-treatment with EPA renders breast cancer cells that overexpress a constitutively active Akt more responsive to the growth inhibitory effects of tamoxifen by approximately 35%.
Conclusions:
These findings suggest that EPA may be useful for the treatment of tamoxifen-resistant breast cancer cells with high levels of activated Akt and provide the rationale to test this hypothesis in the clinic.
Key words: Akt, n-3 fatty acids, tamoxifen
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
J. Chen, K. A. Power, J. Mann, A. Cheng, and L. U. Thompson Flaxseed Alone or in Combination with Tamoxifen Inhibits MCF-7 Breast Tumor Growth in Ovariectomized Athymic Mice with High Circulating Levels of Estrogen Experimental Biology and Medicine, September 1, 2007; 232(8): 1071 - 1080. [Abstract] [Full Text] [PDF] |
||||
![]() |
M Beeram, Q-T. Tan, R. Tekmal, D Russell, A Middleton, and L. deGraffenried Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling Ann. Onc., August 1, 2007; 18(8): 1323 - 1328. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Le Foll, C. Corporeau, V. Le Guen, J.-P. Gouygou, J.-P. Berge, and J. Delarue Long-chain n-3 polyunsaturated fatty acids dissociate phosphorylation of Akt from phosphatidylinositol 3'-kinase activity in rats Am J Physiol Endocrinol Metab, April 1, 2007; 292(4): E1223 - E1230. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-L. Cai, A. R. Tee, J. D. Short, J. M. Bergeron, J. Kim, J. Shen, R. Guo, C. L. Johnson, K. Kiguchi, and C. L. Walker Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning J. Cell Biol., April 24, 2006; 173(2): 279 - 289. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. E. Olivo and L. Hilakivi-Clarke Opposing effects of prepubertal low- and high-fat n-3 polyunsaturated fatty acid diets on rat mammary tumorigenesis Carcinogenesis, September 1, 2005; 26(9): 1563 - 1572. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Chen, E. Hui, T. Ip, and L. U. Thompson Dietary Flaxseed Enhances the Inhibitory Effect of Tamoxifen on the Growth of Estrogen-Dependent Human Breast Cancer (MCF-7) in Nude Mice Clin. Cancer Res., November 15, 2004; 10(22): 7703 - 7711. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. A. deGraffenried, B. Chandrasekar, W. E. Friedrichs, E. Donzis, J. Silva, M. Hidalgo, J. W. Freeman, and G. R. Weiss NF-{kappa}B inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen Ann. Onc., June 1, 2004; 15(6): 885 - 890. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. C. Jordan Targeting antihormone resistance in breast cancer: a simple solution Ann. Onc., July 1, 2003; 14(7): 969 - 970. [Full Text] [PDF] |
||||





